Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines

Novartis AG NVS has agreed to expand its fill-and-finish support for Pfizer Inc PFE / BioNTech SE BNTX COVID-19 vaccine.
Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
Novartis plans to take bulk mRNA active ingredient from BioNTech and fill them into vials under sterile conditions for shipment back to BioNTech for distribution.
This new agreement follows an earlier deal to fill and finish more than 50 million doses in 2021 at the Novartis Stein site in Switzerland.
Related: BioNTech Starts Production At New Germany Plant In Boost For COVID-19 Shots.
Price Action: NVS shares traded higher by 0.31% at $84.73 premarket on the last check Thursday.